Key Points
- Insider sale: Zimmer Biomet insider Sang Yi sold 5,000 shares at an average price of $82.64, totaling about $413,200. After the transaction, Yi still owned 27,251 shares, reducing his stake by 15.5%.
- Strong quarterly results: The company reported Q1 earnings of $2.09 per share, beating estimates of $1.86, on revenue of $2.09 billion. Revenue rose 9.3% year over year, and Zimmer Biomet raised FY2026 guidance to $8.40-$8.55 EPS.
- Dividend and analyst sentiment: Zimmer Biomet declared a quarterly dividend of $0.24 per share, payable July 31, implying a 1.1% annual yield. Analysts currently have a consensus rating of Hold with an average target price of $102.70.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) insider Sang Yi sold 5,000 shares of the stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Zimmer Biomet Trading Up 0.9%
Shares of Zimmer Biomet stock opened at $83.70 on Wednesday. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $108.29. The company has a market cap of $16.19 billion, a price-to-earnings ratio of 21.74, a PEG ratio of 1.92 and a beta of 0.47. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The company's 50-day moving average price is $87.82 and its 200-day moving average price is $90.61.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.23. The company had revenue of $2.09 billion for the quarter, compared to analysts' expectations of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. Zimmer Biomet's revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.
Zimmer Biomet Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet's dividend payout ratio is 24.94%.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of ZBH. M&T Bank Corp grew its position in Zimmer Biomet by 15,705.6% during the fourth quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider's stock valued at $321,158,000 after acquiring an additional 3,548,998 shares during the last quarter. Norges Bank bought a new position in Zimmer Biomet during the fourth quarter valued at approximately $221,234,000. Franklin Resources Inc. grew its position in Zimmer Biomet by 43.2% during the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider's stock valued at $601,204,000 after acquiring an additional 2,017,857 shares during the last quarter. Auto Owners Insurance Co grew its position in Zimmer Biomet by 8,892.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider's stock valued at $180,713,000 after acquiring an additional 1,987,362 shares during the last quarter. Finally, Dodge & Cox grew its position in Zimmer Biomet by 5.1% during the third quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider's stock valued at $2,286,793,000 after acquiring an additional 1,118,710 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on the stock. Citizens Jmp decreased their price objective on shares of Zimmer Biomet from $120.00 to $105.00 and set a "market outperform" rating on the stock in a research report on Wednesday, April 29th. Wall Street Zen upgraded shares of Zimmer Biomet from a "hold" rating to a "buy" rating in a research report on Saturday, May 9th. Weiss Ratings upgraded shares of Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Tuesday, April 7th. Truist Financial restated a "hold" rating and issued a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Zimmer Biomet from $100.00 to $95.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of "Hold" and an average target price of $102.70.
Get Our Latest Report on Zimmer Biomet
About Zimmer Biomet
(
Get Free Report)
Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.
The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
